恩替卡韦联合苦参素治疗慢性乙型肝炎48周疗效观察

doi:10.3969/j.issn.1672-5069.2014.02.018

Abstract

Ren Weixin, Jiao Jian, Liu Mei.. Entecavir and matrine in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 184-185.

[1] Lu FM，Zhuang H．Management of hepatitisB in China．Chin Med J（Engl），2009,122（1）：3-4．
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010 年版）.实用肝脏病杂志，2011，14（2）：81-89.
[3] Zoulim F，Chemin I．Hepatitis B virus induced hepatocellular carcinoma．Cancer Lett，2009，286、（1）：52-59．
[4] 白菡，赵桂珍．抗病毒治疗在慢性乙型肝炎治疗中的重要性．世界华人消化杂志，2008，16（1）：5-9．
[5] 陈彩云，吴庆欢，梁丹，等．拉米夫定和恩替卡韦治疗慢性乙型肝炎的成本-效果分析．中国医药导报，2008，5（26）：101-102．
[6] 曹振环，陈新月. 慢性乙型肝炎抗病毒药物新进展.国际流行病学传染病学杂志，2008，35：417-419.
[7] Mellss AK0，Annas FL. Antiviral options for the treatment of chronic hepatitis B．J Antimicrob Chemother，2006，57（6）：1030-1034．
[8] 徐道振．病毒性肝炎临床实践．北京：人民卫生出版社，2006：35l-355．
[9] 赵攀，王希，祁京，等．拉米夫定耐药株两种治疗策略的效果比较（拉米夫定和阿德福韦酯联用与恩替卡韦单用）．临床军医杂志,2011，39（1）：11-13．
[10] 张宜俊，郑曲波，刘慧萍，等．慢性HBV感染者外周血树突状细胞亚群的检测和分析．上海免疫杂志，200l，6：16-18．
[11] 周红燕，张波，汪铮．苦参素治疗慢性乙型肝炎相关细胞因子的变化．传染病信息，2009，22（4）：230-231.
[12] 蒋海全．拉米夫定联合苦参素治疗慢性乙型肝炎100例临床观察．中国医药指南（学术版），2008，6（10）：60．
[13] 郜志林，张炳煌. 恩替卡韦联合苦参素治疗HbeAg阳性慢性乙型肝炎的疗效观察. 中国中西医结合消化杂志,2010，4（2）:92-94.
[14]王景叶，马玉萍．恩替卡韦联合苦参素片治疗慢性乙型肝炎4l例．陕西医学杂志，2009，38（10）：13-15．

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.

Entecavir and matrine in the treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments